Low-Dose Testosterone for Women: Microdosing Protocols, Evidence, and What Every Life Stage Needs to Know

What "Microdosing" Testosterone Actually Means for Women

The term microdosing, in a clinical context, refers to using testosterone at doses designed to restore physiologic female levels rather than achieve male-range concentrations. For women, the target is a total serum testosterone of roughly 15 to 75 ng/dL, which corresponds to the upper quartile of the normal premenopausal female range. This is roughly one-tenth to one-twentieth of the dose used in male hypogonadism.

There is no single universally accepted "microdosing protocol." What exists is a body of evidence from randomized controlled trials, synthesized in the 2019 Global Consensus Position Statement on Testosterone for Women, that defines a reasonable target range and describes the transdermal route as preferred. The consensus, endorsed by 11 international societies including The Menopause Society and the International Society for Sexual Medicine, states that testosterone therapy should be considered for postmenopausal women with HSDD after adequate evaluation.

Calling it "microdosing" is partly marketing language and partly accurate pharmacology. The doses are genuinely small, and the physiologic goal is restoration, not supraphysiologic enhancement.

Why the Transdermal Route Is Standard

Oral testosterone is not appropriate for women. Oral formulations produce markedly elevated hepatic first-pass metabolites, suppress sex hormone-binding globulin (SHBG), and deliver unpredictable free testosterone levels. The Global Consensus Statement explicitly recommends against oral testosterone for women. Transdermal delivery bypasses first-pass hepatic metabolism, produces steadier serum levels, and allows dose titration that oral forms cannot.

Pellet implants remain controversial. The consensus statement specifically notes that pellets carry a risk of supraphysiologic levels that cannot be reversed once implanted, and calls for caution. They are not a "microdosing" approach in any meaningful pharmacokinetic sense.

The Formulation Problem in the United States

No testosterone product is FDA-approved for women in the US. The 300 mcg/day testosterone patch (Intrinsa) was approved in Europe and demonstrated efficacy in surgical menopause, but was never approved by the FDA, which cited concerns about cardiovascular safety data and the risk of off-label use in younger women. US clinicians therefore rely on compounded transdermal formulations or, occasionally, dose-splitting of male-approved gels (AndroGel 1%, testosterone 2.5 g packets contain 25 mg testosterone, far more than any female dose requires).

Compounded preparations most commonly used in women include 0.5% to 2% testosterone cream or gel, typically applied to the inner wrist, labia majora, or inner thigh in volumes of 0.1 to 0.5 mL daily. The actual delivered dose depends on the compounded concentration and volume, not the percentage alone. A 1% cream applied in 0.1 mL delivers approximately 1 mg testosterone.

The Evidence Base: What the Trials Actually Show

The strongest evidence for female testosterone therapy comes from 36 randomized controlled trials reviewed in the 2019 Global Consensus. These trials enrolled predominantly postmenopausal women (both natural and surgical) and used the 300 mcg/day transdermal patch or equivalent doses of other transdermal formulations.

Sexual Function Outcomes

Across trials, testosterone therapy produced a statistically significant and clinically meaningful improvement in satisfying sexual events, sexual desire, pleasure, arousal, and orgasm compared to placebo. The APHRODITE trial, one of the largest, found that naturally postmenopausal women using 300 mcg/day testosterone patch experienced an increase of approximately 0.8 satisfying sexual events per 4 weeks compared to placebo. The number needed to treat for a meaningful response in desire is approximately 3 to 5, depending on the outcome measure used.

A useful clinical framework for interpreting this effect: testosterone therapy for HSDD produces an effect size comparable to that of flibanserin (Addyi) in premenopausal women, but with a more consistent tolerability profile in postmenopausal patients and without the alcohol interaction risk. Flibanserin carries a black-box warning about hypotension with alcohol; testosterone does not share this mechanism.

What the Evidence Does Not Support

The consensus is explicit about what remains unproven. Testosterone has not been shown in adequately powered randomized trials to improve bone density, cognitive function, mood, fatigue, or body composition in women at physiologic replacement doses. Studies reporting these benefits have generally been underpowered, uncontrolled, or have used supraphysiologic doses. The 2019 consensus states: "There is insufficient evidence to recommend testosterone for any other indication in women." Clinicians and patients should treat claims about testosterone "optimizing" energy, metabolism, or athletic performance in women as extrapolations without high-quality randomized evidence.

The evidence gap for younger women is substantial. Nearly all trial data comes from women aged 40 to 70, predominantly postmenopausal. As the consensus authors note, testosterone therapy in premenopausal women with HSDD lacks the evidence base needed to make a formal recommendation. This does not mean it is never appropriate, but it means the risk-benefit calculation rests on thinner data.

Dosing Protocols by Life Stage

Testosterone physiology changes significantly across a woman's reproductive life. The approach to dosing and monitoring must reflect where you are hormonally.

Postmenopause (Best-Studied Group)

In natural and surgical postmenopause, estrogen declines dramatically and SHBG often decreases, which can transiently raise free testosterone before total testosterone also falls. Most postmenopausal women have total testosterone levels below 20 ng/dL. The therapeutic target is 15 to 75 ng/dL total testosterone by liquid chromatography-tandem mass spectrometry (LC-MS/MS), the gold-standard assay.

Standard compounded protocol: testosterone 0.5 to 1% cream or gel, 1 to 2 mg delivered transdermally once daily. Start at the lower dose and recheck serum total testosterone and SHBG at 6 weeks. Titrate to symptom response and serum level, not to a fixed number alone. The Menopause Society's 2022 position statement on hormone therapy supports use of testosterone for HSDD in postmenopausal women with appropriate monitoring.

Surgical menopause (bilateral oophorectomy) causes an abrupt fall in both estrogen and testosterone. These women may have more pronounced HSDD and often respond more quickly to testosterone therapy. The APHRODITE and related trials specifically demonstrated benefit in this subgroup.

Concurrent adequate estrogen therapy is recommended when testosterone is used in postmenopause. Testosterone is not a substitute for estrogen in managing vasomotor symptoms, genitourinary syndrome of menopause (GSM), or bone protection.

Perimenopause

Perimenopausal testosterone levels are variable and often decline before estrogen does. Symptoms of low libido, fatigue, and diminished arousal in perimenopause may partly reflect falling testosterone, though the evidence is far less clear than in postmenopause.

No adequately powered RCT has specifically studied testosterone microdosing in perimenopause for HSDD. Clinicians who use it in this group do so by analogy to postmenopausal data, targeting the same serum range but acknowledging the extrapolation. The menstrual cycle itself causes testosterone fluctuations, with peaks in the follicular and ovulatory phases, which complicates timing of serum measurements. Blood draws for monitoring in perimenopausal women should be taken in the early follicular phase (days 2 to 5) when possible, to get a stable baseline.

Reproductive Years and PCOS

Women with PCOS already have elevated androgens, including testosterone. Using exogenous testosterone in women with PCOS is generally not indicated and risks worsening hyperandrogenism, acne, hirsutism, and cycle irregularity. PCOS guidelines from ASRM and ESHRE do not recommend testosterone therapy for this group.

For women in their reproductive years without PCOS who report HSDD, testosterone is sometimes used off-label, but the evidence base is thin and the Global Consensus Statement does not endorse this as a standard recommendation. Any use in premenopausal women must be accompanied by reliable contraception (see Pregnancy and Lactation section below).

Postpartum and Lactation

The postpartum period involves a complex hormonal reset. Testosterone levels are low in early postpartum and recover gradually. Postpartum low libido is common but is multifactorial: sleep deprivation, estrogen-progesterone withdrawal, prolactin elevation, and psychological adjustment all contribute. Testosterone therapy is not indicated in this period and is contraindicated during breastfeeding.

Pregnancy and Lactation: Non-Negotiable Safety Information

Testosterone is contraindicated in pregnancy. It is classified as FDA Pregnancy Category X. Exogenous testosterone causes virilization of a female fetus, including clitoral enlargement, labial fusion, and other genital abnormalities. The risk exists throughout the first and second trimesters when external genitalia are forming. This is not theoretical. Case reports document fetal virilization from maternal testosterone exposure.

Any woman of reproductive potential who is prescribed testosterone must use highly effective contraception. Acceptable methods include an intrauterine device (IUD), subdermal implant, tubal ligation, or combined hormonal contraception. A progestin-only pill is not considered maximally reliable in this context because of the interaction between androgens and progestin metabolism. If you are trying to conceive, testosterone must be discontinued at least 3 months before any conception attempt, and ideally longer.

Testosterone transfers into breast milk. Animal and limited human data show that exogenous androgens appear in breast milk and could affect a nursing infant's development. The Global Consensus Statement states that testosterone should not be used in women who are breastfeeding. Postpartum women who wish to use testosterone for HSDD should wait until breastfeeding has ceased and reliable contraception is in place.

If you become pregnant while using testosterone, stop immediately and contact your obstetric provider. Document the exposure and timing for your care team.

Side Effects, Monitoring, and the Supraphysiologic Risk

At physiologic replacement doses, testosterone is generally well tolerated in women. The most common side effects are androgenic and dose-related.

Common Side Effects

Acne is the most frequently reported side effect, occurring in roughly 20 to 30% of women in trials at standard doses. Application site reactions occur with patch formulations. Hair growth at the application site can occur with labia majora application. Oily skin and mild hirsutism may appear, particularly if serum levels drift above the target range.

Clitoral enlargement has been reported, particularly with supraphysiologic levels or with pellet implants. At microdosing levels targeting the physiologic range, this is uncommon but should prompt a dose reduction if it occurs.

Voice changes (deepening) are rare at physiologic doses but irreversible once established. This makes monitoring essential.

Monitoring Schedule

• Baseline: Total testosterone by LC-MS/MS, SHBG, free testosterone (calculated), complete blood count, lipid panel.
• 6 weeks after starting or any dose change: Total testosterone and SHBG to assess absorption and level.
• 3 months: Full repeat panel.
• Ongoing: Every 6 to 12 months once stable.

The Global Consensus is explicit that immunoassay-based testosterone measurements are unreliable in women at the low end of the female range. LC-MS/MS should be specified on the lab order. Most major reference labs offer this; it may require explicit ordering.

If total testosterone exceeds 75 to 100 ng/dL on repeat testing, reduce the dose. Do not continue therapy at supraphysiologic levels and monitor for irreversible androgenic effects.

Cardiovascular and Breast Safety

The 2019 consensus reviewed available data and found no evidence that testosterone at physiologic replacement doses increases cardiovascular risk, breast cancer risk, or endometrial cancer risk in postmenopausal women. The cardiovascular safety data is reassuring within the trial timeframes studied (up to 24 months), but long-term data beyond two years is limited. Women with pre-existing cardiovascular disease, polycythemia, or active breast cancer should discuss individualized risk with their clinician.

Testosterone can raise hematocrit. At female doses this is rarely clinically significant, but a baseline CBC and periodic recheck are standard practice.

Who This Is Right For, and Who It Is Not

Getting this decision right requires thinking by life stage and by condition, not by symptom alone.

Women Who May Benefit

Postmenopausal women with diagnosed HSDD (defined as distressing loss of sexual desire not explained by relationship factors, mental health conditions, or medications) who have already received adequate estrogen therapy and treatment of genitourinary syndrome of menopause are the population with the strongest evidence for testosterone. The Global Consensus recommends a biopsychosocial assessment before prescribing, including ruling out depression, relationship distress, and contributory medications (SSRIs, hormonal contraceptives, antihistamines).

Women with surgical menopause from bilateral oophorectomy, particularly those who experienced abrupt onset of low libido after surgery, have a biologically clear rationale and good trial evidence supporting therapy.

Perimenopausal women with consistent low libido not explained by mood, relationship, or sleep factors may be candidates, with the understanding that this is off-label with thinner evidence.

Women for Whom Testosterone Is Not Recommended

• Pregnant women or those trying to conceive without stopping therapy first.
• Breastfeeding women.
• Women with active or history of hormone-sensitive cancer (discuss case by case with oncology).
• Women with PCOS and existing hyperandrogenism.
• Women whose low libido is explained by treatable causes (depression, SSRI side effects, GSM, relationship conflict) that have not yet been addressed.
• Women seeking testosterone for non-HSDD indications (energy, muscle, cognition) without an evidence-based diagnosis: the data simply does not support this use at current evidence levels.

Adolescents and women under 25 have essentially no trial data, and testosterone should not be used in this age group outside of carefully supervised endocrine conditions.

Compounding Quality: A Real Clinical Concern

Because no FDA-approved female testosterone product exists in the US, the quality of compounded preparations varies by pharmacy. A 2017 analysis of compounded testosterone products found significant variability in concentration and potency between compounding pharmacies, with some products delivering substantially more or less testosterone than labeled. This variability makes serum monitoring even more important: you cannot rely on the dose label alone to predict your serum level.

Use pharmacies that are PCAB-accredited (Pharmacy Compounding Accreditation Board) when possible, and always confirm the vehicle (cream vs. Gel) because absorption differs between vehicles. Gel formulations generally produce more consistent serum levels than cream formulations, though cream applied to labia majora absorbs more reliably than cream applied to keratinized skin.

What a Realistic Treatment Conversation Should Include

Before starting testosterone, a thorough clinician conversation should cover all of the following.

What HSDD evaluation has been completed, and have reversible causes been ruled out? Has genitourinary syndrome of menopause been diagnosed and treated? What estrogen therapy, if any, is in place? What is the plan for contraception if you are premenopausal? Which pharmacy will be used, and is it PCAB-accredited? What is the monitoring schedule and what serum levels would prompt a dose change or discontinuation?

The Global Consensus authors write: "We recommend that testosterone therapy for women should be prescribed to achieve serum testosterone concentrations in the normal physiological female range in order to avoid side effects." Staying in that range, confirmed by LC-MS/MS at regular intervals, is what separates safe clinical use from the unmonitored supraphysiologic territory that has given testosterone therapy for women a complicated reputation.

A 3-month trial is reasonable to assess response. If there is no improvement in HSDD symptoms after 6 months of therapy at therapeutic serum levels, the diagnosis and treatment plan should be re-evaluated rather than escalating the dose.